FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:335-342 July 24, 2003 Number 4 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Schröder, F. H. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The sensitivity and specificity of a screening test are biased when disease status is not verified in all subjects and when the likelihood of confirmation depends on the test result itself. We assessed the screening characteristics of the prostate-specific antigen (PSA) measurement after correction for verification bias.

Methods Between 1995 and 2001, 6691 men underwent PSA-based screening for prostate cancer. Of these men, 705 (11 percent) subsequently underwent biopsy of the prostate. Under the assumption that the chance of undergoing a biopsy depends only on the PSA-test result and other observed clinical variables, we used a mathematical model to estimate adjusted receiver-operating-characteristic (ROC) curves.

Results Adjusting for verification bias significantly increased the area under the ROC curve (i.e., the overall diagnostic performance) of the PSA test, as compared with an unadjusted analysis (0.86 vs. 0.69, P<0.001, for men less than 60 years of age; 0.72 vs. 0.62, P=0.008, for men 60 years of age or older). If the threshold PSA value for undergoing biopsy were set at 4.1 ng per milliliter, 82 percent of cancers in younger men and 65 percent of cancers in older men would be missed. A digital rectal examination that is abnormal but not suspicious for cancer does not affect the overall performance characteristics of the test.

Conclusions A lower threshold level of PSA for recommending prostate biopsy, particularly in younger men, may improve the clinical value of the PSA test.

Source Information

From the Joint Center for Radiation Therapy, Harvard Medical School, Boston (R.S.P.); the Department of Radiation Oncology, Brigham and Women's Hospital and the Dana–Farber Cancer Institute, Boston (A.V.D.); the Division of Urologic Surgery, Washington University School of Medicine, St. Louis (W.J.C., K.A.R.); the Department of Urology, Northwestern University, Fineberg School of Medicine, Chicago (W.J.C.); and the Department of Health Policy and Management, Harvard School of Public Health, Boston (K.M.K.).

Address reprint requests to Dr. Kuntz at the Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Ave., Boston, MA 02115-5924, or at kmk{at}hsph.harvard.edu.

Full Text of this Article

Related Letters:

Verification Bias in Screening for Prostate Cancer
Leiner S., Chatterton H. T., Punglia R. S., Catalona W. J., Kuntz K. M.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:1672-1673, Oct 23, 2003. Correspondence

This article has been cited by other articles:

• Arneth, B. M. (2009). Clinical Significance of Measuring Prostate-Specific Antigen. Lab Med 40: 487-491 [Abstract] [Full Text]  
• Auvinen, A., Raitanen, J., Moss, S., de Koning, H. J., Hugosson, J., Tammela, T., Roobol, M., Lilja, H., Hakama, M. (2009). Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the Netherlands. Cancer Epidemiol. Biomarkers Prev. 18: 2000-2005 [Abstract] [Full Text]  
• Himes, B. E., Dai, Y., Kohane, I. S., Weiss, S. T., Ramoni, M. F. (2009). Prediction of Chronic Obstructive Pulmonary Disease (COPD) in Asthma Patients Using Electronic Medical Records. J. Am. Med. Inform. Assoc. 16: 371-379 [Abstract] [Full Text]  
• Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R. C. Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P. (2008). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin. Chem. 54: e11-e79 [Abstract] [Full Text]  
• Eekers, D. B. P., Laschet, A., de Groot, M., Roelofs, E., Kester, A., Delaere, K., Lambin, P., van Gils, F., Nap, M., ten Kate, J. (2008). Why determine only the total prostate-specific antigen, if the free-to-total ratio contains the information?. Ann Clin Biochem 45: 270-274 [Abstract] [Full Text]  
• Haas, G. P., Delongchamps, N. B., Jones, R. F., Chandan, V., Serio, A. M., Vickers, A. J., Jumbelic, M., Threatte, G., Korets, R., Lilja, H., de la Roza, G. (2007). Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Detection Based on True Prevalence. JNCI J Natl Cancer Inst 99: 1484-1489 [Abstract] [Full Text]  
• Bundy, D. G., Byerley, J. S., Liles, E. A., Perrin, E. M., Katznelson, J., Rice, H. E. (2007). Does This Child Have Appendicitis?. JAMA 298: 438-451 [Abstract] [Full Text]  
• Holsinger, T., Deveau, J., Boustani, M., Williams, J. W. Jr (2007). Does This Patient Have Dementia?. JAMA 297: 2391-2404 [Abstract] [Full Text]  
• Lauer, M. S., Murthy, S. C., Blackstone, E. H., Okereke, I. C., Rice, T. W. (2007). [18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography for Diagnosis of Suspected Lung Cancer: Impact of Verification Bias. Arch Intern Med 167: 161-165 [Abstract] [Full Text]  
• Lee, S. E., Byun, S.-S., Park, H. K., Shim, H. B., Ku, J. H. (2006). Detection of Prostate Cancer at Low and Intermediate Serum Prostate-Specific Antigen Levels in a Country with a Low Incidence of Prostate Cancer. Jpn J Clin Oncol 36: 376-380 [Abstract] [Full Text]  
• Catalona, W. J., Loeb, S., Han, M. (2006). Viewpoint: expanding prostate cancer screening.. ANN INTERN MED 144: 441-443 [Abstract] [Full Text]  
• Punglia, R. S., Kuntz, K. M., Catalona, W. J., D'Amico, A. (2005). Operating Characteristics of Prostate-Specific Antigen and Verification Bias. JAMA 294: 2698-2698 [Full Text]  
• Ankerst, D. P., Chi, C., Thompson, I. M. (2005). Operating Characteristics of Prostate-Specific Antigen and Verification Bias--Reply. JAMA 294: 2698-2699 [Full Text]  
• Klein, E. A., Tangen, C. M., Goodman, P. J., Lippman, S. M., Thompson, I. M. (2005). Assessing Benefit and Risk in the Prevention of Prostate Cancer: The Prostate Cancer Prevention Trial Revisited. JCO 23: 7460-7466 [Abstract] [Full Text]  
• Hricak, H (2005). MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br. J. Radiol. 78: S103-S111 [Abstract] [Full Text]  
• van Asperen, C J, Brohet, R M, Meijers-Heijboer, E J, Hoogerbrugge, N, Verhoef, S, Vasen, H F A, Ausems, M G E M, Menko, F H, Gomez Garcia, E B, Klijn, J G M, Hogervorst, F B L, van Houwelingen, J C, van't Veer, L J, Rookus, M A, van Leeuwen, F E, on behalf of the Netherlands Collaborative Group o, (2005). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J. Med. Genet. 42: 711-719 [Abstract] [Full Text]  
• Soletormos, G., Semjonow, A., Sibley, P. E.C., Lamerz, R., Petersen, P. H., Albrecht, W., Bialk, P., Gion, M., Junker, F., Schmid, H.-P., Van Poppel, H., on behalf of the European Group on Tumor Markers, (2005). Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice. Clin. Chem. 51: 1342-1351 [Abstract] [Full Text]  
• Thompson, I. M., Ankerst, D. P., Chi, C., Lucia, M. S., Goodman, P. J., Crowley, J. J., Parnes, H. L., Coltman, C. A. Jr (2005). Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower. JAMA 294: 66-70 [Abstract] [Full Text]  
• Garzotto, M., Beer, T. M., Hudson, R. G., Peters, L., Hsieh, Y.-C., Barrera, E., Klein, T., Mori, M. (2005). Improved Detection of Prostate Cancer Using Classification and Regression Tree Analysis. JCO 23: 4322-4329 [Abstract] [Full Text]  
• Bradley, S. V., Oravecz-Wilson, K. I., Bougeard, G., Mizukami, I., Li, L., Munaco, A. J., Sreekumar, A., Corradetti, M. N., Chinnaiyan, A. M., Sanda, M. G., Ross, T. S. (2005). Serum Antibodies to Huntingtin Interacting Protein-1: A New Blood Test for Prostate Cancer. Cancer Res. 65: 4126-4133 [Abstract] [Full Text]  
• Gu, Z., Rubin, M. A., Yang, Y., Deprimo, S. E., Zhao, H., Horvath, S., Brooks, J. D., Loda, M., Reiter, R. E. (2005). Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer. Clin. Cancer Res. 11: 2237-2243 [Abstract] [Full Text]  
• Saiag, P., Bernard, M., Beauchet, A., Bafounta, M.-L., Bourgault-Villada, I., Chagnon, S. (2005). Ultrasonography Using Simple Diagnostic Criteria vs Palpation for the Detection of Regional Lymph Node Metastases of Melanoma. Arch Dermatol 141: 183-189 [Abstract] [Full Text]  
• Etzioni, R., Falcon, S., Gann, P. H., Kooperberg, C. L., Penson, D. F., Stampfer, M. J. (2004). Prostate-Specific Antigen and Free Prostate-Specific Antigen in the Early Detection of Prostate Cancer: Do Combination Tests Improve Detection?. Cancer Epidemiol. Biomarkers Prev. 13: 1640-1645 [Abstract] [Full Text]  
• Claus, F. G., Hricak, H., Hattery, R. R. (2004). Pretreatment Evaluation of Prostate Cancer: Role of MR Imaging and 1H MR Spectroscopy. RadioGraphics 24: S167-S180 [Abstract] [Full Text]  
• Alibhai, S. M.H. (2004). What is the prevalence of prostate cancer among men with low prostate-specific antigen levels?. CMAJ 171: 572-572 [Full Text]  
• Blackstone, E. H., Lauer, M. S. (2004). Caveat emptor: The treachery of work-up bias. J. Thorac. Cardiovasc. Surg. 128: 341-344 [Full Text]  
• Morgentaler, A. (2004). A 66-Year-Old Man With Sexual Dysfunction. JAMA 291: 2994-3003 [Full Text]  
• Sreekumar, A., Laxman, B., Rhodes, D. R., Bhagavathula, S., Harwood, J., Giacherio, D., Ghosh, D., Sanda, M. G., Rubin, M. A., Chinnaiyan, A. M. (2004). Humoral Immune Response to {alpha}-Methylacyl-CoA Racemase and Prostate Cancer. JNCI J Natl Cancer Inst 96: 834-843 [Abstract] [Full Text]  
• Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., Crowley, J. J., Coltman, C. A. Jr. (2004). Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level <=4.0 ng per Milliliter. NEJM 350: 2239-2246 [Abstract] [Full Text]  
• Kuller, L. H., Thomas, A., Grandits, G., Neaton, J. D. (2004). Elevated Prostate-Specific Antigen Levels Up to 25 Years Prior to Death from Prostate Cancer. Cancer Epidemiol. Biomarkers Prev. 13: 373-377 [Abstract] [Full Text]  
• Law, M. (2004). Screening without evidence of efficacy. BMJ 328: 301-302 [Full Text]  
• Rhoden, E. L., Morgentaler, A. (2004). Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring. NEJM 350: 482-492 [Full Text]  
• Davis, A. M (2003). High result in prostate specific antigen test: Repeated testing and free tests might help. BMJ 327: 1227-1227 [Full Text]  
• Henderson, A. R. (2003). A Triptych of Statistics. Clin. Chem. 49: 1959-1962 [Full Text]  
• Leiner, S., Chatterton, H. T., Punglia, R. S., Catalona, W. J., Kuntz, K. M. (2003). Verification Bias in Screening for Prostate Cancer. NEJM 349: 1672-1673 [Full Text]  
• Gottlieb, S. (2003). Study shows poor reliability of prostate cancer test. BMJ 327: 249-249 [Full Text]  
• Schroder, F. H., Kranse, R. (2003). Verification Bias and the Prostate-Specific Antigen Test -- Is There a Case for a Lower Threshold for Biopsy?. NEJM 349: 393-395 [Full Text]